Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5% – Should You Sell?

05 Jan 2026, 15:00 by Scott Moore · The Cerbat Gem

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) traded down 5.5% on Monday . The company traded as low as $9.10 and last traded at $9.0790. 68,974 shares changed hands during trading, a decline of 88% from the average session volume of 598,162 shares. The stock had previously closed at $9.61.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LXEO. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. Guggenheim started coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Leerink Partners lifted their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Chardan Capital restated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Check Out Our Latest Stock Analysis on LXEO

Lexeo Therapeutics Stock Down 2.9%

The stock’s 50 day moving average price is $9.50 and its two-hundred day moving average price is $6.87. The firm has a market capitalization of $681.36 million, a price-to-earnings ratio of -3.46 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.15. On average, equities analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Insider Transactions at Lexeo Therapeutics

In other news, insider Eric Adler sold 3,382 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the transaction, the insider owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This represents a 4.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tai Sandi See sold 3,888 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the transaction, the insider owned 65,862 shares in the company, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 24,646 shares of company stock worth $221,037. 5.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC bought a new position in shares of Lexeo Therapeutics during the 2nd quarter worth about $60,000. Savant Capital LLC acquired a new stake in Lexeo Therapeutics in the 2nd quarter valued at $119,000. Ethic Inc. bought a new stake in shares of Lexeo Therapeutics in the 2nd quarter worth about $44,000. Palumbo Wealth Management LLC acquired a new stake in shares of Lexeo Therapeutics during the second quarter worth approximately $226,000. Finally, Affinity Asset Advisors LLC raised its position in Lexeo Therapeutics by 142.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock valued at $14,429,000 after purchasing an additional 2,108,474 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.